A Retrospective Analysis of Central and Peripheral Metabolic Characteristics in Patients with Cryptococcal Meningitis
ConclusionMetabolic and structural alterations in the brain may be associated with peripheral metabolic changes. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 20, 2024 Category: Neurology Source Type: research
Group-Based Trajectory Modeling of Fluid Balance in Elderly Patients with Acute Ischemic Stroke: Analysis from Multicenter ICUs
ConclusionDaily FB trajectories were associated with adverse outcomes in elderly patients with AIS. Regular assessment of daily fluid status and restriction of FO are crucial for the recovery of critically ill patients. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 18, 2024 Category: Neurology Source Type: research
Chinese Translation and Validation of the Center for Neurologic Study Lability Scale
ConclusionThe Chinese version of the CNS-LS demonstrated good sensitivity and specificity in the group of patients with ALS enrolled in this study. The CNS-LS should be a useful instrument for clinical and research purposes for patients in this language group. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 16, 2024 Category: Neurology Source Type: research
Vascular Endothelial Growth Factor and Ischemic Stroke Risk: A Mendelian Randomization Study
ConclusionsThis Mendelian randomization study found no relationship between genetically predisposed serum VEGF levels and risks of IS or its subtypes. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 15, 2024 Category: Neurology Source Type: research
Methotrexate and the Risk of Dementia: A Two-Sample Mendelian Randomization Study
ConclusionThe findings of this mendelian randomization (MR) study suggest a potential causal effect of methotrexate use on the risk of dementia. However, further research is needed to validate these findings and explore the underlying mechanisms. Since methotrexate is widely prescribed for various autoimmune diseases, a better understanding of its potential impact on dementia risk is crucial for optimizing treatment strategies and addressing potential adverse effects. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 9, 2024 Category: Neurology Source Type: research
Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis
AbstractThe number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older persons with MS may be more susceptible to infections, hospitalisations and malignancy. Aging people with MS have higher rates of comorbidities versus aged-matched controls, increasing the individual risk of disability. We review the therapeutic properties of cladribine tablets (CladT) in ageing people with RMS, with regard to their utility for allowing these individuals to cease continuous administration of a DMT (i.e. to act as an “exit ther...
Source: Neurology and Therapy - April 8, 2024 Category: Neurology Source Type: research
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
ConclusionGalcanezumab exhibited post-treatment efficacy for up to 4 months in Japanese patients with EM and with CM. No unexpected safety signals were observed.Clinical Trial RegistrationClinicalTrials.gov, NCT02959177 and NCT02959190. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 6, 2024 Category: Neurology Source Type: research
Donanemab in Japanese Patients with Early Alzheimer ’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
ConclusionsThe overall efficacy and safety of donanemab in Japanese participants were similar to the global TRAILBLAZER-ALZ 2 population.Trial registrationClinicalTrials.gov identifier: NCT04437511. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 6, 2024 Category: Neurology Source Type: research
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
ConclusionsData from an integrated analysis of studies in TD and an integrated analysis of studies of chorea in HD showed that deutetrabenazine has a favorable safety profile and is well tolerated across indications.Trial RegistrationClinicalTrials.gov identifiers, NCT02291861, NCT02195700, NCT01795859, NCT02198794, NCT01897896. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 1, 2024 Category: Neurology Source Type: research
Anti-N-methyl-d-aspartate Receptor Encephalitis in People Living with HIV: Case Report and Literature Review
AbstractWith the increase in the number of cases of autoimmune encephalitis (AE), the cerebrospinal fluid (CSF) of people living with HIV (PLWH) showing abnormal behavior, cognitive impairment or abnormal movements should be actively screened for the antibody panel of AE. Early recognition and treatment can prevent severe seizures or coma and markedly improve the prognosis of patients. The first-line immunotherapy for AE includes intravenous methylprednisolone and immunoglobulin. However, whether long-time immunosuppressive maintenance therapy is needed is debated. For PLWH, immunosuppressive therapy and even steroids coul...
Source: Neurology and Therapy - March 26, 2024 Category: Neurology Source Type: research
REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program
ConclusionsVery high adherence rates independent of the PSP nursing service over 1 year of treatment indicate that IFN beta-1a sc is an easy-to-use and well-tolerated disease-modifying drug.Trial Registration NumberVfa.de: No. 892.https://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/nisdb/nis-details/_892. (Source: Neurology and Therapy)
Source: Neurology and Therapy - March 26, 2024 Category: Neurology Source Type: research
Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study
ConclusionsVutrisiran demonstrated benefit in neurologic function and other key efficacy measures versus external placebo across all four baseline neuropathy severity quartiles. Patients initiating vutrisiran earlier in their disease course retained the highest neurologic function level after 18 months, highlighting the importance of early diagnosis and treatment.Trial Registration NumberClinicalTrials.gov: NCT03759379. (Source: Neurology and Therapy)
Source: Neurology and Therapy - March 21, 2024 Category: Neurology Source Type: research
Publisher Correction: Summary of Research: What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation
(Source: Neurology and Therapy)
Source: Neurology and Therapy - March 19, 2024 Category: Neurology Source Type: research
Correction: Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment
(Source: Neurology and Therapy)
Source: Neurology and Therapy - March 18, 2024 Category: Neurology Source Type: research
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France
AbstractCladribine tablets (CladT) has been available for therapeutic use in France since March 2021 for the management of highly active relapsing multiple sclerosis (RMS). This high-efficacy disease-modifying therapy (DMT) acts as an immune reconstitution therapy. In contrast to most high-efficacy DMTs, which act via continuous immunosuppression, two short courses of oral treatment with CladT at the beginning of years 1 and 2 of treatment provide long-term control of MS disease activity in responders to treatment, without the need for any further pharmacological treatment for several years. Although the labelling for Clad...
Source: Neurology and Therapy - March 15, 2024 Category: Neurology Source Type: research
